Search
SARS-CoV-2 Clinical Trials
A listing of 4 SARS-CoV-2 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 4 of 4
There are currently 4 active clinical trials seeking participants for SARS-CoV-2 research studies. The states with the highest number of trials for SARS-CoV-2 participants are Texas, Florida, California and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
Recruiting
The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/19/2025
Locations: Headlands Research Scottsdale, Scottsdale, Arizona +16 locations
Conditions: Influenza, SARS-CoV-2
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of t... Read More
Gender:
ALL
Ages:
Between 6 months and 5 years
Trial Updated:
03/07/2025
Locations: Trinity Clinical Research, LLC, Bessemer, Alabama +73 locations
Conditions: SARS-CoV-2
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
Recruiting
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland +5 locations
Conditions: SARS-CoV-2
Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment
Recruiting
Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3).
Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor.
Methods:
Patients who were... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/07/2021
Locations: Hunt Regional Medical Center, Greenville, Texas
Conditions: SARS-CoV-2, Hypoxia, ARDS
1 - 4 of 4